基因工程工具市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、治療領域、最終用戶、地區和競爭格局分類，2021-2031年）

全球基因工程工具市場預計將從2025年的220.9億美元成長到2031年的285.7億美元，複合年成長率（CAGR）為4.38%。這些工具包括專用平台、酵素和試劑，例如限制性內切酶和CRISPR-Cas9，用於改造基因組材料，應用於科研、農業和醫療保健領域。市場成長要素：需要精準基因治療的遺傳疾病發病率不斷上升，以及全球對基因改造作物的需求日益成長，以增強糧食安全。此外，對基因組研究基礎設施和合成生物學的大量投資為這些技術奠定了堅實的基礎，確保了其在產業波動中的穩定性。

然而，該行業面臨著許多挑戰，包括由於嚴格的監管要求和與脫靶效應相關的倫理問題，導致新治療方法核准流程漫長。儘管研發活動十分活躍，但這種複雜的合規環境仍對商業化構成重大障礙。根據美國基因與細胞治療學會 (ASGCT) 的報告，到 2025 年，全球開發平臺仍將保持強勁勢頭，屆時將有超過 3200 項 RNA、細胞和基因療法的臨床試驗正在進行中。

市場促進因素

基因編輯平台，特別是CRISPR-Cas9技術的快速發展，是推動基因編輯產業成長的關鍵催化劑。 CRISPR-Cas9技術已從實驗室概念發展成為臨床驗證的治療方法。這項進步迫使工具供應商開發高度精密、精準的試劑和自動化系統，以滿足人體應用所需的嚴格標準。精準醫療運動將基因編輯工具的品質與基因療法的商業性成功直接連結起來。例如，2024年1月，Vertex Pharmaceuticals宣布其首個用於治療輸血依賴型BETA-地中海貧血的CRISPR/Cas9基因編輯療法CASGEVY已獲得美國FDA核准。這是一個里程碑式的成就，展現了這些現代基因編輯技術的成熟度與效用。

同時，生物技術公司和基因組學研究領域私人和公共資金的大幅成長推動了先進工程設備的購買。大規模的資本注入使新興生物製藥公司能夠擴展其研發能力，從而增加了從設備製造商採購硬體和耗材的數量。這種融資動能不僅限於Start-Ups，也延伸至支持新興平台技術的大型企業聯合組織。 2025年3月，《Fierce Biotech》報道稱，Xaira Therapeutics已籌集創紀錄的10億美元資金，用於推進人工智慧主導的藥物發現。這種強勁的投資環境正在支撐供應鏈並帶來實際成果。再生醫學聯盟在2025年指出，上年度共有9種新產品核可，顯示市場對檢驗的工具的需求持續強勁。

市場挑戰

全球基因工程工具市場面臨許多挑戰，包括嚴格的法規結構和關於脫靶效應的倫理擔憂。這些合規要求迫使研發人員進行廣泛而漫長的安全測試，以證明基因編輯干預不會導致意外的基因組改變。因此，治療候選藥物從臨床研究到商業化生產的進程有顯著延遲。這種延誤直接阻礙了工具供應商的市場擴張，因為從小規模研究試劑到大規模商業採購的過渡被持續推遲。

監管瓶頸的影響體現在活躍開發平臺與實際上市產品之間的巨大差距。根據再生醫學聯盟統計，2024年全球僅9種新產品獲得核准。如此有限的商業核准數量限制了大規模基因工程產品的潛在市場。因此，隨著業界努力應對將這些技術應用於患者的複雜核准流程，工具製造商的先進平台收入成長正在放緩。

市場趨勢

利用人工智慧最佳化引導RNA設計，從根本上改變了基因工程工具的開發方式，最大限度地減少了試驗造成的延誤。開發人員正在使用平台模型以驚人的速度預測分子交互作用，從而能夠生產具有高度特異性且脫靶風險較低的基因編輯工具。這項技術進步直接支持了複雜基因組修飾所需的高精度試劑的生成。例如，NVIDIA於2025年2月宣布，其基於約9兆個鹼基對訓練的平台模型「Evo 2」能夠準確預測基因序列以及蛋白質的功能和結構。

同時，基因編輯技術在氣候適應農業領域的進步，正催生一個專注於多功能、高通量植物育種系統的市場區隔。與人類治療不同，該領域需要廣泛的編輯功能，以提高不同地區作物對環境壓力的耐受性。這一趨勢包括將專有的編輯架構授權給全球研究團隊，以加速改良主糧作物的推廣應用。例如，2025年6月，Pairwise公司宣布將其Fulcrum平台授權給國際玉米和甘薯改良中心（CIMMYT），以加速20個國家的性狀開發。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因工程工具市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（基因組規模編輯工具、基因組規模工程工具）
  • 依治療領域（鐮狀細胞疾病、心臟病、糖尿病、阿茲海默症、肥胖、其他）
  • 依最終用戶（生技/製藥公司、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美基因工程工具市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲基因工程工具市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區基因工程工具市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲基因工程工具市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲基因工程工具市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球基因工程工具市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Lonza
• Cibus
• Recombinetics Inc.
• Sangamo
• Merck KGaA
• Precision Biosciences
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• Caribou Biosciences Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Genetic Engineering Tool Market is projected to expand from USD 22.09 Billion in 2025 to USD 28.57 Billion by 2031, reflecting a CAGR of 4.38%. These tools consist of specialized platforms, enzymes, and reagents-such as restriction nucleases and CRISPR-Cas9-used to alter genomic material for applications in research, agriculture, and medicine. The market is chiefly driven by the rising incidence of genetic diseases, which demands precise gene therapies, and the growing global need for genetically modified crops to bolster food security. Furthermore, significant investments in genomic research infrastructure and synthetic biology provide a solid foundation for these technologies, offering stability amidst industry fluctuations.

Nevertheless, the industry encounters substantial obstacles due to rigorous regulatory requirements and ethical issues related to off-target effects, which frequently extend the approval timelines for new treatments. This intricate compliance environment imposes significant barriers to commercialization, even with high levels of research engagement. As reported by the American Society of Gene & Cell Therapy, the global development pipeline remained strong in 2025, featuring over 3,200 active clinical trials for RNA, cell, and gene therapies.

Market Driver

A primary catalyst for growth is the rapid technological evolution of genome editing platforms, specifically the progression of CRISPR-Cas9 from a laboratory concept to a clinically proven therapeutic method. This advancement forces tool providers to engineer highly refined, high-fidelity reagents and automated systems that satisfy the strict standards necessary for human use. The trend toward precision medicine establishes a direct connection between the quality of engineering tools and the commercial success of gene therapies. For example, Vertex Pharmaceuticals announced in January 2024 that the US FDA approved CASGEVY, the first CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta-thalassemia, a milestone that validates the maturity and utility of these modern editing suites.

Concurrently, a significant increase in private and public funding for biotechnology ventures and genomic research is driving the acquisition of advanced engineering instrumentation. Large capital infusions allow emerging biopharmaceutical firms to expand their R&D capabilities, thereby boosting the purchase volume of hardware and consumables from tool manufacturers. This financial momentum extends beyond startups to major syndicates backing new platform technologies; Fierce Biotech reported in March 2025 that Xaira Therapeutics raised a record $1 billion to further AI-led drug discovery. Such a strong investment landscape supports the supply chain and results in tangible outcomes, with the Alliance for Regenerative Medicine noting in 2025 that the sector saw nine new product approvals the previous year, maintaining demand for validated tools.

Market Challenge

The Global Genetic Engineering Tool Market faces a formidable barrier in the form of strict regulatory frameworks and ethical issues regarding off-target effects. These compliance demands compel developers to undertake extensive and prolonged safety studies to demonstrate that gene-editing interventions do not induce unintended genomic changes. As a result, the progression of therapeutic candidates from clinical research to commercial manufacturing faces significant delays. This slowdown directly impedes market expansion for tool providers, as the expected transition from low-volume research reagent use to high-volume commercial procurement is continually pushed back.

The consequences of this regulatory bottleneck are highlighted by the gap between the active development pipeline and actual market launches. According to the Alliance for Regenerative Medicine, the sector managed only nine new product approvals globally in 2024. This restricted number of commercial authorizations limits the addressable market for large-scale genetic engineering supplies. Consequently, tool manufacturers experience slower revenue growth from their advanced platforms, as the industry grapples with navigating the intricate approval processes necessary to deliver these technologies to patients.

Market Trends

The incorporation of artificial intelligence to optimize guide RNA design is fundamentally transforming the creation of genetic engineering tools by minimizing trial-and-error delays. Developers are utilizing foundation models to predict molecular interactions with exceptional speed, enabling the production of highly specific editors that reduce off-target risks. This technological advancement directly supports the generation of high-fidelity reagents needed for complex genomic modifications. For instance, NVIDIA announced in February 2025 that its Evo 2 foundation model, trained on nearly 9 trillion nucleotides, is now available to accurately forecast the function and form of genetic sequences and proteins.

Simultaneously, the growth of gene editing in climate-resilient agriculture is fostering a specific market segment dedicated to versatile, high-throughput plant breeding systems. In contrast to human therapeutics, this sector requires broad-spectrum editing suites that can improve crop endurance against environmental stressors in various regions. This trend involves licensing proprietary editing architectures to global research groups to speed up the deployment of enhanced staple crops. As an example, Pairwise announced in June 2025 that it licensed its Fulcrum platform to CIMMYT to accelerate trait development across 20 countries.

Key Market Players

• Thermo Fisher Scientific Inc.
• Lonza
• Cibus
• Recombinetics Inc.
• Sangamo
• Merck KGaA
• Precision Biosciences
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• Caribou Biosciences Inc.

Report Scope

In this report, the Global Genetic Engineering Tool Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Engineering Tool Market, By Type

• Genome Scale Editing Tools
• Genome Scale Engineering Tools

Genetic Engineering Tool Market, By Therapeutic Area

• Sickle Cell Disease
• Heart Disease
• Diabetes
• Alzheimer's Disease
• Obesity
• Others

Genetic Engineering Tool Market, By End User

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Genetic Engineering Tool Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genetic Engineering Tool Market.

Available Customizations:

Global Genetic Engineering Tool Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genetic Engineering Tool Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Genome Scale Editing Tools, Genome Scale Engineering Tools)
  • 5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
  • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Genetic Engineering Tool Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genetic Engineering Tool Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Genetic Engineering Tool Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Genetic Engineering Tool Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Genetic Engineering Tool Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genetic Engineering Tool Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Genetic Engineering Tool Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Genetic Engineering Tool Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Genetic Engineering Tool Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Genetic Engineering Tool Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Genetic Engineering Tool Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genetic Engineering Tool Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Genetic Engineering Tool Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Genetic Engineering Tool Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Genetic Engineering Tool Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Genetic Engineering Tool Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Genetic Engineering Tool Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genetic Engineering Tool Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Genetic Engineering Tool Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Genetic Engineering Tool Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Genetic Engineering Tool Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genetic Engineering Tool Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Genetic Engineering Tool Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Genetic Engineering Tool Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genetic Engineering Tool Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza
• 15.3. Cibus
• 15.4. Recombinetics Inc.
• 15.5. Sangamo
• 15.6. Merck KGaA
• 15.7. Precision Biosciences
• 15.8. OriGene Technologies Inc.
• 15.9. Intellia Therapeutics Inc.
• 15.10. Caribou Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer